D-1100-2020 Class II Ongoing

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1100-2020 was initiated by Teva Pharmaceuticals USA on March 25, 2020 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is ongoing. Affected quantity: N/A.

Recall Details

Product Type
Drugs
Report Date
April 15, 2020
Initiation Date
March 25, 2020
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
N/A

Product Description

LOSARTAN POTASSIUM TABLETS, USP 25 mg, Bulk, Rx only, For Further Manufacturing, Packing or Repackaging only, Manufactured by: Arrow Pharma (Malta) Ltd., Birzebbugia Malta NDC 0591-3745-00

Reason for Recall

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Distribution Pattern

Bulk product was distributed to one re-packager in California.

Code Information

Lots 1207344A, exp. date 06/2020; 1207343A, 1207342A, exp. date 07/2020